文献速递炎症性肠病

生物制剂和小分子药物治疗溃疡性直肠炎的结局:一项比利时多中心队列研究

Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-07-11

这项比利时多中心回顾性队列研究纳入167例活动性溃疡性直肠炎患者,共接受223个疗程的先进治疗(生物制剂和小分子药物)。36.3%的治疗疗程达到短期无激素临床缓解,在多变量分析中,初治生物制剂患者、接受维得利珠单抗治疗者、内镜疾病活动度为中度者及体重指数<25 kg/m2者更常达到主要终点;维得利珠单抗治疗者及病程较短者药物持续性显著更高,未观察到新的安全性信号。

要点

  • 溃疡性直肠炎患者接受先进治疗后,36.3%的治疗疗程达到短期无激素临床缓解。
  • 多变量分析显示,初治生物制剂、维得利珠单抗、内镜中度活动及体重指数<25 kg/m2与更常达到主要终点相关。
  • 维得利珠单抗治疗者及病程较短者药物持续性显著更高,未观察到新的安全性信号。

核心结论

  • 先进治疗对病变局限于直肠的溃疡性结肠炎患者同样有效且安全。
  • 应考虑将溃疡性直肠炎患者纳入未来的随机对照试验。

研究设计与样本

  • 多中心回顾性队列研究,纳入连续的活动性溃疡性直肠炎患者(Mayo内镜子评分≥2,直肠炎症范围达15 cm),这些患者在常规治疗失败后启动先进治疗。
  • 共167例连续患者(52.0%为女性;中位年龄41.0岁;82.0%为初治生物制剂),接受223个疗程的溃疡性直肠炎治疗(阿达木单抗38、戈利木单抗14、英夫利西单抗54、乌司奴单抗9、维得利珠单抗99、托法替布9)。
  • 主要终点为短期无激素临床缓解(总Mayo评分≤2且各单项评分均不大于1)。
  • 同时评估药物持续性、无复发生存和无结肠切除生存,并进行二元逻辑回归和Cox回归分析。

主要发现

  • 36.3%的治疗疗程达到主要终点。
  • 多变量分析显示,主要终点在初治生物制剂患者(P = .001)、接受维得利珠单抗治疗的患者(P = .001)、内镜疾病活动度为中度的患者(P = .002)以及体重指数<25 kg/m2的患者(P = .018)中更常达到。
  • 药物持续性在接受维得利珠单抗治疗的患者(P < .001)和病程较短的患者(P = .006)中显著更高。
  • 未观察到新的安全性信号。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Several advanced therapies (biologic therapies and small molecules) have been approved for the treatment of moderate-to-severe ulcerative colitis. The registration trials for these agents typically excluded patients with isolated proctitis, leaving an evidence gap. We evaluated efficacy and safety of advanced therapies in patients with ulcerative proctitis (UP). METHODS: This multicenter retrospective cohort study included consecutive patients with active UP (Mayo endoscopy subscore of ≥2, rectal inflammation up to 15 cm) initiating advanced therapy, after failing conventional therapy. The primary end point was short-term steroid-free clinical remission (total Mayo score ≤2 with no individual subscore >1). In addition, drug persistence and relapse-free and colectomy-free survival were assessed. Both binary logistic and Cox regression analyses were performed. RESULTS: In total, 167 consecutive patients (52.0% female; median age 41.0 years; 82.0% bionaive) underwent 223 courses of therapy for UP (38 adalimumab, 14 golimumab, 54 infliximab, 9 ustekinumab, 99 vedolizumab, 9 tofacitinib). The primary end point was achieved with 36.3% of the treatment courses, and based on multivariate analysis, more commonly attained in bionaive patients (P = .001), patients treated with vedolizumab (P = .001), patients with moderate endoscopic disease activity (P = .002), and a body mass index <25 kg/m2 (P = .018). Drug persistence was significantly higher in patients treated with vedolizumab (P < .001) and patients with a shorter disease duration (P = .006). No new safety signals were observed. CONCLUSIONS: Advanced therapies are also efficacious and safe in patients with ulcerative colitis limited to the rectum. Therefore, the inclusion of patients with UP in future randomized-controlled trials should be considered.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Lemmens P, Louis E, Van Moerkercke W, et al. Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study. Clin Gastroenterol Hepatol. 2023. PMID: 37442318. doi:10.1016/j.cgh.2023.06.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。